Stephen Oliver former Customs Investigator and Matt Lawson Barrister are both experts in the cannabinoid industry, they are the founders of The Canna Consultants and will be speaking at the event on both days.
Please wait, loading...
We have reproduced the questions as they have been submitted in order not to interfere with them. If you are unable to answer the question as drafted, we would encourage you to answer what you feel is the import of the question in order that market participant is not disadvantaged by potentially poor language selection in their phraseology.
Is the FSA's policy that any CBD "New to Market" products will be treated differently than those "Already on the Market" justified despite there being no difference in their potential risks? Perhaps the more telling question is whether the policy will be sustained in the face of an inevitable legal challenge?